Direct-To-Consumer (DTC) branded drug Web sites risk presentation and implications for public policy

Journal of Advertising

Volumn 36, Issue 3, 2007, Pages 123-135

  Sheehan, Kim Bartel ^a  

^a UNIVERSITY OF OREGON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34948819244     PISSN: 00913367     EISSN: None     Source Type: Journal    
DOI: 10.2753/JOA0091-3367360310     Document Type: Article

References (51)

1. Anderson, James C. (2004), "Consumers of E-Health," Social Science Computer Review, 22 (2), 242-248.
2. Andrews, J. Craig, Richard G. Netemeyer, and Scot Burton (1998), "Consumer Generalization of Nutrient Content Claims in Advertising," Journal of Marketing, 62 (4), (October), 62-75.
3. Barlett, Donald L., James B. Steele, Laura Karmatz, Barbara Kiviat, and Joan Levinstein (2004), "Why We Pay So Much for Drugs," Time (February 2), 163.
4. Bell, Robert A., Richard L. Kravitz, and Michael S. Wilkes (2000), "Direct-to-Consumer Prescription Drug Advertising, 1989-1998: A Content Analysis of Conditions, Targets, Inducements, and Appeals," Journal of Family Practice, 49 (4), 329-335.
5. Berkowitz, Lyle, Mary D. Capizzi, Jennifer Breuer, and Joanne Szuminski (2002), "Effective DTC Product Web Sites Must Synthesize Advertising and Labeling Requirements," Pharmaceutical Executive, 21 (4), 124-128.
6. Bettman, James R., John W. Payne, and Richard Staelin (1986), "Cognitive Considerations in Designing Effective Labels for Presenting Risk Information," Journal of Public Policy and Marketing, 5 (1), 1-28.
7. Brannon, Leah (1999), "Regulating Drug Promotion on the Internet" Food and Drug Law Journal, 54, 599-621.
8. Calfee, John E. (2002), "Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs," Journal of Public Policy and Marketing, 21 (2), 174-193.
9. Drummy, W (2002), "A Fine Line," available at www.pharmexec. com (accessed July 17, 2003).
10. Entman, R. (1993), "Framing: Toward Clarification of a Fractured Paradigm," Journal of Communication, 49(1), 103-122.
11. Federal Food, Drug, and Cosmetic Act (FFDCA) (2004a), Part 202: Prescription Drug Advertising (21 CFR 202.1(e) (7)(viii)).
12. _ (2004b), Part 201: Definitions (21 CFR) 201 (n).
13. Federal Trade Commission (FTC) (2000), "Facts for Businesses: Dot Com Disclosures," available at www.ftc.gov/bcp/ conline/pubs/buspubs/ dotcom/ (accessed June 24, 2007).
14. Food and Drug Administration (FDA) (2004), "Guidance for Industry: Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements," available at www.fda.gov/cder/guidance/5669dft.pdf (accessed January 15, 2006).
15. _ (2005a), Warning Letter to Calcitrol, available at www.fda.gov/cder/ warn/warn2005.htm (accessed May 18, 2006).
16. _ (2005b), Warning Letter to Quadramet, available at www.fda.gov/cder/ warn/warn2005.htm (accessed May 18, 2006).
17. _ (2005c), Warning Letter to VisionBlue, available at www.fda.gov/cder/warn/warn2005.htm (accessed May 18, 2006).
18. _ (2005d), Warning Letter to Cipro, available at www.fda.gov/cder/warn/ warn2005.htm (accessed May 18, 2006).
19. _ (2005e), Warning Letter to Tracleer, available at www.fda.gov/cder/ warn/warn2005.htm (accessed May 18, 2006).
20. Food and Drug Administration Center for Drug Evaluation and Research (CDER) (1999), "Guidance for Industry: Consumer-Directed Broadcast Advertisements" (August 9), Federal Register, 64 (152), 43197-43198 (Docket 97D0302).
21. Green, Kristen (1998), "Marketing Health Care Products on the Internet: A Call for Updated Federal Regulations," American Journal of Law and Medicine, 24 (2 and 3), 365-386.
22. Harris Interactive (2002), "The Internet as a Health Information Resource," Harris Poll, May 21, 2002.
23. Hoy, Mariea Grubbs, and J. Craig Andrews (2004), "Adherence of Prime-Time Televised Advertising Disclosures to the 'Clear and Conspicuous' Standard: 1990 Versus 2002,"Journal of Public Policy and Marketing, 23 (1), 170-182.
24. Huh, Jisu, and Brenda J. Cude (2004), "Is the Information 'Fair and Balanced' in Direct-to-Consumer Prescription Web Sites?" Journal of Health Communication, 9(6), 529-540.
25. IMS (2005), "Total U.S. Promotional Spend by Type, 2004," available at www.imshealth.com/ims/portal/front/ articleC/0,2777, 6599_49695992_75406357,00.html (accessed May 16, 2006).
26. Lexchin, Joel, and Barbara Mintzes (2002), "Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No," Journal of Public Policy and Marketing, 21 (2), 194-201.
27. Lynch, Patrick J., and Sarah Horton (2002), Web Style Guide, Basic Design Principles for Creating Web Sites, New Haven: Yale University Press.
28. Macias, Wendy, and Liza Stavchansky Lewis (2003/2004), "A Content Analysis of Direct-to-Consumer (DTC) PrescriptionDrug Web Sites," Journal of Advertising, 32 (4), 43-56.
29. Martin-Facklam, Meret, Michael Kostrzewa, Peter Martin, and Walter Haefeli (2004), "Quality of Drug Information on the World Wide Web and Strategies to Improve Pages with Poor Information Quality," British Journal of Clinical Pharmacology, 57 (2), 80-87.
30. McKillen, Dan (2003), "Web Watch," Medical Marketing and Media, 38 (1), 10.
31. Med Ad News (2006), "DTC Takes a Back Seat," available at www.pharmalive.com/magazines/medad/view.cfm?articleID=3522 (accessed June 27, 2006).
32. Medical Marketing and Media (2002), "FDA Mulling Guidance on Internet Promotion," Medical Marketing and Media, 37 (1), 32.
33. Mehta, Abhilasha, and Scott C. Purvis (2003), "Consumer Response to Print Prescription Drug Advertising, "Journal of Advertising Research, 43, 2 (June), 194-206.
34. Melton, Arthur W. (1970), "The Situation with Respect to the Spacing of Repetitions and Memory," Journal of 'Verbal Learning and Verbal Behavior, 9, 596-606.
35. Menon, Ajit M., Aparna D. Deshpande, Matthew Perri III, and George Zinkhan (2003), "Consumers' Attention to the Brief Summary in Print Direct-to-Consumer Advertisements Perceived Usefulness in Patient-Physician Discussions," Journal of Public Policy and Marketing, 22 (2), 181-191.
36. Moore, Patrick A., and Michael D. Newton (1998), "Prescription Drug Advertising on the Internet: A Proposal for Regulation," West Virginia Journal of Law and Technology, 2 (February 14), available at www.wvu.edu/-law/wvjolt/Arch/Moore/ Moore.htm (accessed June 27, 2007).
37. Morkes, John, and Jakob Nielsen (1997), "Concise, Scannable and Objective: How to Write for the Web," Sun Microsystems, available at www.useit.com/papers/webwriting/writing.html (accessed March 15, 2007).
38. Norman, Don (1999), "Commentary: Banner Blindness, Human Cognition and Web Design," Internetworking (March), available at www.internettg.org/newsletter/mar99/commentary.html (accessed June 26, 2007).
39. Opderbeck, David W. (1998), "How Should FDA Regulate PtescriptionDrug Promotion on the Internet?" Food and Drug Law Journal, 53 (1), 47-61.
40. Paulukonis, AnnMarie (2000), "The Use of Schemas by Students Taking Their First Online Course," Teaching With Technology Newsletter, 5 (5), www.uwsa.edu/ttt/paulukon.htm (accessed June 26, 2007).
41. Roth, Martin S. (1996), "Patterns in Direct-to-Consumer Prescription Drug Print Advertising and Their Public Policy Implications," Journal of Public Policy and Marketing, 15 (1), 63-75.
42. Scheineson, Marc J. (1996), "Legal Overview of Likely FDA Regulation of Internet Promotion," Food and Drug Law Journal, 51 (4), 697-716.
43. Schwartz, Neil L., Laurie S. Ellsworth, Lorraine Graham, and Bruce Knight (1998), "Accessing Prior Knowledge to Remember Text: A Comparison of Advance Organizers and Maps," Contemporary Educational Psychology, 23 (1), 65-89.
44. Scott, W. (1955), "Reliability of Content Analysis: The Case of Nominal Scale Coding," Public Opinion Quarterly, 17 (3), 321-325.
45. Thomaselli, Rich (2005), "The Side Effects of DTC Change," Advertising Age, 76 (33), 1.
46. _, and Tobi Elkin (2003), "Web Thrives as DTC Platform," Advertising Age, 74 (45), 21.
47. Unnava, H. Rao, and Robert E. Burnkrant (1991), "Effects of Repeating Varied Ad Executions on Brand Name Memory," Journal of Marketing Research, 28 (2), 406-416.
48. Wechsler, Jill (1999), "FDA Struggles over Policies Affecting PBMs and Internet Marketing," Formulary, 34 (12), 1054-1055.
49. Wilkes, Michael S., Robert A. Bell, and Richard L. Kravitz (2000), "Direct-to-Consumer Prescription Drug Advertising: Trends, Impact, and Implications," Health Affairs, 19 (2).
50. Wilkie, William L. (1986), "Affirmative Disclosure at the FTC: Strategic Dimension," Journal of Public Policy and Marketing, 5, 123-130.
51. Wray, Donna (2004), "Driving Efficient DTC Online: A Marketer's Toolkit," DTC Perspectives, 3 (1), 62-66.